Gregor Awang, Director, Biologics Process Development
24+ years of experience developing upstream and recombinant-protein downstream processes and tech transferring these processes from lab to manufacturing scale
Past roles with: Cangene Corporation, Emergent BioSolutions
PhD, Industrial Microbiology from University of Saskatchewan, M.Sc. Environmental Microbiology from University of Manitoba
Joined BIOVECTRA in 2019
Jean-Francois Vincent-Rocan - Director, Complex Chemistry Process Development
Ph.D. in Chemistry from University of Ottawa
Graduate Diploma in Scientific Management and Leadership
B.Sc Bio-pharmaceutical Science from University of Ottawa
10+ years’ experience in complex chemistry
Joined BIOVECTRA in 2018 and was appointed to Director, Process Development in 2023
Facilitated and oversees a collaboration with the Université de Montréal’s Charette Group
Author of 14 publications in method and process development
Krista Affleck - Director, Analytical Development
Master of Science degree from the University of Prince Edward Island (2002).
Hired by BIOVECTRA as a Quality Control Chemist (2002).
Joined R&D group as Research Technician in 2003.
Joined Analytical Chemistry group in 2008.
Promoted to Group Leader on the Analytical Chemistry group in 2012.
In 2014, became the Manager, Analytical Support, and Development in the R&D group.
In 2018, became the Director, Analytical Development.
Ankur Deshpande – Director, Process Development Quality
M.Sc. in Organic Chemistry from The University of New Brunswick (2008)
Has 12 years of experience in the pharmaceutical industry in analytical services and quality
Joined BIOVECTRA in 2010 as a QC Chemist
Oliver Technow - Chief Executive Officer
Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
More than 20 years of global pharmaceutical industry experience.
Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ; in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
Appointed President of BIOVECTRA Inc., December 10, 2015.
Board Director for BIOTECanada
Member of the Steering Council of Innovative Medicines Canada (IMC)
In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
In November 2019, promoted to Chief Executive Officer at BIOVECTRA
In June 2020, named new Chair of PEI BioAlliance Board of Directors